VCIM
IMCR icon

Velan Capital Investment Management’s Immunocore IMCR Stock Holding History

Velan Capital Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,000
Closed -$9.89M – 35
2023
Q1 		$9.89M Sell
200,000
-5,974
-3% -$336K 8.43% 4
2022
Q4 		$11.8M Sell
205,974
-87,411
-30% -$4.92M 10.38% 3
2022
Q3 		$13.8M Hold
293,385
– – 13.66% 3
2022
Q2 		$10.9M Hold
293,385
– – 11.1% 4
2022
Q1 		$8.77M Hold
293,385
– – 8.14% 5
2021
Q4 		$10M Buy
+293,385
New +$10.6M 7.8% 4

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Velan Capital Investment Management's IMCR Position: Q2 2023 in Review

Velan Capital Investment Management sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 200,000 shares — an estimated $9.89M sold.

Velan Capital Investment Management first reported a position in IMCR in Q4 2021 and held it in 6 quarters. The position peaked at $13.8M in Q3 2022. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

  • Velan Capital Investment Management reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
  • Velan Capital Investment Management sold 200,000 Immunocore shares in Q2 2023, an estimated $9.89M.
  • Velan Capital Investment Management first reported a position in Immunocore in Q4 2021 and held it in 6 quarters.
  • Velan Capital Investment Management's Immunocore position peaked at $13.8M in Q3 2022.
  • 120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Velan Capital Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.